Trevena
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
955 Chesterbrook Blvd Ste 110, Chesterbr...Phone Number
(610) 354-8840Website
www.trevena.comRevenue
<$5 MillionStock Symbol
TRVNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company's novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.Explore more
Trevena Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Trevena your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Trevena launches new products
Check out if Trevena is spiking on competitors!
Click to see if Trevena had a recent Job posting/layoffs
Check if Trevena has recently received funding, and reach out quickly before it becomes old news!
Trevena, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Trevena
Funding: Get notified immidiatlly once Trevena has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Trevena recently announced quarterly report
Recommended Actions
Find VP level buyers at Trevena
Find 2 more new buyers
Compare Similar Companies to Trevena
Compare insights from companies similar to Trevena, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Trevena is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Trevena is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Trevena.
Trevena financials insights
Gather financial insights about Trevena, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$64.8M
2022
Other Financing Round
$40M
2023
Share Placement
$4M
2024
Debt
$2M
Trevena Tech Stack
A closer look at the technologies used by Trevena
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Trevena is planning to move offices in August 2025. The move will impact approximately 50 employees at the existing office located at 1018 West 8Th Avenue, Suite A, King Of Prussia, PA.
Facilities Relocation/Expansion
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Earnings
Trevena News & Media
Trevena Announces Receipt of Nasdaq Delisting Notification
CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common stock from The Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s failure to comply with the minimuTrevena Announces Reverse Stock Split
CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on TuesdaTrevena Reports Second Quarter 2024 Results and Provides Business Update
TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in preclinical modelsTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones
Read more news
Top Manufacturing Companies
Frequently Asked Questions Regarding Trevena
Sign Up For FreeTo access detailed company insights
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analge... Read More
